Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer

Table 5 Relationship between mutation of EGFR gene in exon E21 and clinical parameters

	Clinical parameters	No.	EGFR-E21		Positive rate (%)	χ²	p value
	Clinical parameters	No.	Wild type	Mutant type	Positive rate (%)	χ²	p value
Age	≤60	112	84	24	21.43	0.159	0.923
Age	>60	109	84	21	19.27	0.159	0.923
Gender	Male	114	96	13	11.40	11.741	0.003
Gender	Female	107	72	32	29.91	11.741	0.003
Sample type	Tissue sample	194	142	45	23.20	8.171	0.086
	Whole blood sample	22	21	0	0
	Whole blood + tissue sample	5	5	0	0
Pathological type	Squamous cell carcinoma	15	14	0	0	9.627	0.141
	Adenocarcinoma	155	113	38	24.52
	Adenosquamous carcinoma	7	5	1	14.29
Staging	Stage IA	22	15	7	31.82	26.220	0.024
	Stage IB	51	33	17	33.33
	Stage IIA	8	7	1	12.50
	Stage IIB	9	8	0	0
	Stage IIIA	23	14	7	30.43
	Stage IIIB	5	4	0	0
	Stage IV	33	27	6	18.18
Treatment	Surgery	67	40	25	37.31	18.020	0.006
	Chemotherapy	37	31	4	10.81
	Surgery + chemotherapy	66	54	9	13.64

Data are adjusted for age, gender, sample type, pathological type, staging, and treatment method

ISSN: 1477-7819